Rebecca J. Peterson
Investor Relations Contact bij EXICURE, INC.
Actieve functies van Rebecca J. Peterson
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
EXICURE, INC. | Investor Relations Contact | - | - |
Public Communications Contact | - | - | |
National Investor Relations Institute
National Investor Relations Institute Miscellaneous Commercial ServicesCommercial Services National Investor Relations Institute operates as an association of corporate officers and investor relations consultants responsible for communication among corporate management, shareholders, securities analysts and other financial community constituents. The company was founded by DeWitt C. Morrill in 1969 and is headquartered in Alexandria, VA. | Corporate Officer/Principal | 01-01-1998 | - |
Loopbaan van Rebecca J. Peterson
Eerdere bekende functies van Rebecca J. Peterson
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
Alkermes, Inc.
Alkermes, Inc. Pharmaceuticals: MajorHealth Technology Alkermes, Inc. develops and manufactures pharmaceutical products. It offers medicines for the treatment of central nervous system (CNS) diseases. The company was founded by Michael A. Wall, Floyd E. Bloom, Frederick W. K. Brown, Paul R. Schimmel and Alexander G. Rich in 1987 and is headquartered in Waltham, MA. | Investor Relations Contact | - | - |
Public Communications Contact | 11-08-2009 | 01-01-2015 | |
Corporate Officer/Principal | 01-01-2000 | 11-08-2009 | |
ALKERMES PLC | Public Communications Contact | 01-01-2000 | 01-01-2015 |
Millennium Pharmaceuticals, Inc.
Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | Public Communications Contact | 01-01-1997 | 01-01-2000 |
DICERNA PHARMACEUTICALS, INC. | Public Communications Contact | 22-02-2019 | - |
Opleiding van Rebecca J. Peterson
University of Massachusetts | Undergraduate Degree |
Tufts University School of Medicine | Graduate Degree |
Emerson College | Graduate Degree |
Statistieken
Internationaal
Verenigde Staten | 9 |
Ierland | 2 |
Operationeel
Public Communications Contact | 5 |
Investor Relations Contact | 2 |
Corporate Officer/Principal | 2 |
Sectoraal
Health Technology | 6 |
Consumer Services | 4 |
Commercial Services | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
Beursgenoteerde bedrijven | 2 |
---|---|
ALKERMES PLC | Health Technology |
EXICURE, INC. | Health Technology |
Bedrijven in privébezit | 4 |
---|---|
Alkermes, Inc.
Alkermes, Inc. Pharmaceuticals: MajorHealth Technology Alkermes, Inc. develops and manufactures pharmaceutical products. It offers medicines for the treatment of central nervous system (CNS) diseases. The company was founded by Michael A. Wall, Floyd E. Bloom, Frederick W. K. Brown, Paul R. Schimmel and Alexander G. Rich in 1987 and is headquartered in Waltham, MA. | Health Technology |
Millennium Pharmaceuticals, Inc.
Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | Health Technology |
National Investor Relations Institute
National Investor Relations Institute Miscellaneous Commercial ServicesCommercial Services National Investor Relations Institute operates as an association of corporate officers and investor relations consultants responsible for communication among corporate management, shareholders, securities analysts and other financial community constituents. The company was founded by DeWitt C. Morrill in 1969 and is headquartered in Alexandria, VA. | Commercial Services |
Dicerna Pharmaceuticals, Inc.
Dicerna Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Dicerna Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in discovering, developing and commercializing medicines that are designed to leverage ribonucleic acid interference (RNAi) to selectively silence genes that cause or contribute to disease. The firm uses its proprietary GalXC RNAi technology platform to build a pipeline in these therapeutic areas. The company was founded by Douglas M. Fambrough III, Mark A. Behlke, Roberto Guerciolini, James Craig Jenson, and John J. Rossi in October 2006 and is headquartered in Lexington, MA. | Health Technology |
- Beurs
- Insiders
- Rebecca J. Peterson
- Ervaring